TY  - JOUR
AU  - Hernández-Boluda, Juan Carlos
AU  - Pereira, Arturo
AU  - Pastor-Galán, Irene
AU  - Alvarez-Larrán, Alberto
AU  - Savchuk, Alisa
AU  - Puerta, José Manuel
AU  - Sánchez-Pina, José María
AU  - Collado, Rosa
AU  - Díaz-González, Alvaro
AU  - Angona, Anna
AU  - Sagüés, Miguel
AU  - García-Gutiérrez, Valentín
AU  - Boqué, Concepción
AU  - Osorio, Santiago
AU  - Vallansot, Rolando
AU  - Palomera, Luis
AU  - Mendizábal, Arantxa
AU  - Casado, Luis Felipe
AU  - Pérez-Encinas, Manuel
AU  - Pérez-López, Raúl
AU  - Ferrer-Marín, Francisca
AU  - Sánchez-Guijo, Fermín
AU  - García, Carmen
AU  - Heras, Natalia de Las
AU  - López-Lorenzo, José Luis
AU  - Cervantes, Francisco
AU  - Steegmann, Juan Luis
AU  - Grupo Español de Leucemia Mieloide Crónica (GELMC)
PY  - 2018
DO  - 10.1038/s41408-018-0125-0
UR  - http://hdl.handle.net/10668/13270
T2  - Blood cancer journal
AB  - Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but its...
LA  - en
KW  - Aged
KW  - Anticarcinogenic Agents
KW  - Biomarkers
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Follow-Up Studies
KW  - Fusion Proteins, bcr-abl
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Protein Kinase Inhibitors
KW  - Recurrence
KW  - Treatment Outcome
TI  - Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
TY  - research article
VL  - 8
ER  -